Propofol Brings on the Light for Depression Therapy

作     者：Yun Yan Hongli Ma Jing Zhao 

作者机构：Department of AnesthesiologyChina-Japan Friendship HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing100029China 

出 版 物：《Neuroscience Bulletin》 (神经科学通报（英文版）)

年 卷 期：2023年第39卷第12期

页      面：1891-1894页

核心收录：

学科分类：1002[医学-临床医学] 100203[医学-老年医学] 10[医学] 

主　　题：anesthesia drugs Therapy 

摘      要：Major depressive disorder(MDD)is a major cause of global disability,with a global prevalence of 4.4%[1].Anhedonia is a core feature of MDD,and is associated with the longer treatment-resistant course:a third to half of patients with MDD had no response to multiple antidepressants[2].It is crucial to search the more effective target therapeutics for anhedonia to develop new *** is currently the most popular intravenous agent used for general clinical anesthesia and exerts its effect by activating-aminobutyric acid type A(GABAA)receptors.